Bronchial Thermoplasty for Severe Asthma: Initial Experience in Chile

Procedural and short-term safety of bronchial thermoplasty in clinical practice: evidence from a national registry and Hospital Episode Statistics

“…There has been little information published to date about the safety of BT in routine clinical practice in people with more severe asthma than those who took part in the trials. A case series of 8 patients [12] and another of 4 patients [13] demonstrated safety of BT in more severe asthmatics. In addition, a study of 10 patients in a centre which previously took part in the trials did not find any safety concerns at 12 months post-procedure [14].…”

Efficacy and safety of bronchial thermoplasty in clinical practice: a prospective, longitudinal, cohort study using evidence from the UK Severe Asthma Registry

“…Several case series have been published, reporting on BT in clinical practice 12–17. These and an interim analysis from a large manufacturer-sponsored study18 all demonstrate some improvement in quality of life, reductions in exacerbations and healthcare resource utilisation and, in general, concur with the findings of the clinical trials that BT is safe, with none raising any serious concerns.…”

Indirect comparison of bronchial thermoplasty versus omalizumab for uncontrolled severe asthma

“…Logistic regression analysis data from the AIR2 trial did not confirm any treatment effect modification based on baseline variables, including those indicative of baseline asthma severity. Moreover, evidence from the early RISA clinical trial [22] and several case series [24][25][26][27][28][29] shows BT to be similarly effective in patients more severely affected by their asthma than those included in the AIR2 trial. On the OM side of the comparison, a pooled analysis of data from seven RCTs involving 4308 patients, 93% of which had severe asthma, has shown that baseline characteristics do not reliably predict benefit with OM, although there was a suggestion of a greater treatment effect in patients with lower percentagepredicted FEV1 values and higher IgE [30][31][32][33], and more recently, in those with a higher serum eosinophil count, serum periostin or fractionated exhaled nitric oxide [34].…”